NCT04840745View on ClinicalTrials.gov

The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1

PHASE1UnknownINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

October 31, 2021

Study Completion Date

November 30, 2021

Conditions
Early Puberty
Interventions
DRUG

CKD-841 A-1 3.75mg

Single injection, subcutaneous injection

DRUG

CKD-841 A-1 1.88mg

Single injection, subcutaneous injection

DRUG

CKD-841 D 2.92mg

Single injection, subcutaneous injection

DRUG

Leuplin Inj. 3.75 mg

Single injection, subcutaneous injection

Trial Locations (1)

03722

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Severance Hospital

OTHER

lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT04840745 - The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1 | Biotech Hunter | Biotech Hunter